Real‐world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain
Objectives This study aimed to describe the real‐world therapeutic management of patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) (LUTS/BPH) attending primary care and urology clinics in Spain. Methods This observational, retrospective, multicentre study in...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical practice (Esher) 2021-08, Vol.75 (8), p.e14250-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 8 |
| container_start_page | e14250 |
| container_title | International journal of clinical practice (Esher) |
| container_volume | 75 |
| creator | Miñana, Bernardino Molero, José María Agra Rolán, Alfonso Martínez‐Fornes, Miguel Téllez Cuervo Pinto, Rafael Lorite Mingot, David Carreño, Ágata Palacios‐Moreno, Juan Manuel |
| description | Objectives
This study aimed to describe the real‐world therapeutic management of patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) (LUTS/BPH) attending primary care and urology clinics in Spain.
Methods
This observational, retrospective, multicentre study included men ≥50 years of age diagnosed with LUTS/BPH (≤8 years prior to study visit) (N = 670). Therapeutic management according to healthcare service (primary care vs. urology clinics) or progression criteria, proportion of patients with treatment change, patient profile according to therapy and evolution of LUTS severity were assessed.
Results
Overall differences were noticed in the management of patients between healthcare service (P |
| doi_str_mv | 10.1111/ijcp.14250 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8365648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2553445365</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4480-7287d3fbd2502d7b2556db077faa194308b0cdc5b2c38dea11f4c81010e941e93</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS1ERduBDQ-ALLFBlVLs2EmcDVI1otCqEoifteU4NzMeOXawk45m1wUPwDPyJDidoQIWeGPL5_PRPT4IPafknKb12mz0cE55XpBH6IRWPM9ozunjdGalyArC6DE6jXFDSF4UgjxBx4wJwStan6Dvn0DZn3c_tj7YFo9rCGqAaTQa98qpFfTgRqxci-HW23TvHfYdHtRokhDx1oxr3IAzK4eH4OOo5qfr3QBhsCoahc0smF6FHdYqwL3XFLz1q92sfR6UcU_RUadshGeHfYG-Xr79snyf3Xx4d7W8uMk054JkVS6qlnVNm5LmbdWkNGXbkKrqlKI1Z0Q0RLe6aHLNRAuK0o5rQQklUHMKNVugN3vfYWp6aHWKEJSVh_mkV0b-rTizlit_KwUri5KLZPDqYBD8twniKHsTNVirHPgpyrygpWD1PMwCvfwH3fgpuBQvUQXjvEieiTrbUzp9XgzQPQxDiZzLlXO58r7cBL_4c_wH9HebCaB7YGss7P5jJa-ulx_3pr8A3Oezfw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553445365</pqid></control><display><type>article</type><title>Real‐world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Miñana, Bernardino ; Molero, José María ; Agra Rolán, Alfonso ; Martínez‐Fornes, Miguel Téllez ; Cuervo Pinto, Rafael ; Lorite Mingot, David ; Carreño, Ágata ; Palacios‐Moreno, Juan Manuel</creator><creatorcontrib>Miñana, Bernardino ; Molero, José María ; Agra Rolán, Alfonso ; Martínez‐Fornes, Miguel Téllez ; Cuervo Pinto, Rafael ; Lorite Mingot, David ; Carreño, Ágata ; Palacios‐Moreno, Juan Manuel</creatorcontrib><description>Objectives
This study aimed to describe the real‐world therapeutic management of patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) (LUTS/BPH) attending primary care and urology clinics in Spain.
Methods
This observational, retrospective, multicentre study included men ≥50 years of age diagnosed with LUTS/BPH (≤8 years prior to study visit) (N = 670). Therapeutic management according to healthcare service (primary care vs. urology clinics) or progression criteria, proportion of patients with treatment change, patient profile according to therapy and evolution of LUTS severity were assessed.
Results
Overall differences were noticed in the management of patients between healthcare service (P < .001) and with or without progression criteria (P < .05). Most patients received pharmacological treatment at diagnosis (70.7%; 474/670), which increased at study visit (81.6%; 547/670) with overall similar profiles between primary care and urology clinics for each therapy. α1‐Blockers were the most used pharmacological treatment across healthcare settings at diagnosis (61.8%; 293/474) and study visit (51%; 279/547). Only 27.1% (57/210) of patients with progression criteria at diagnosis and 35.6% (99/278) at study visit received 5α‐reductase inhibitor (5ARI) alone or in combination with a α1‐blocker. Overall, most patients did not change treatment (60%; 402/670) with a trend of more patients worsening in symptoms when not receiving α1‐blocker plus 5ARI combination therapy.
Conclusion
Most patients with LUTS/BPH received pharmacological treatment; however, most men with progression criteria did not receive a 5ARI alone or in combination. These results support the need to reinforce both primary care and urologists existing clinical guideline recommendations for the appropriate medical management of patients with LUTS/BPH.</description><identifier>ISSN: 1368-5031</identifier><identifier>EISSN: 1742-1241</identifier><identifier>DOI: 10.1111/ijcp.14250</identifier><identifier>PMID: 33884719</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Diagnosis ; Disease management ; Drug therapy ; Genital diseases ; Hyperplasia ; Original Paper ; Original Papers ; Patients ; Primary care ; Urinary tract ; Urology</subject><ispartof>International journal of clinical practice (Esher), 2021-08, Vol.75 (8), p.e14250-n/a</ispartof><rights>2021 The Authors. Practice published by John Wiley & Sons Ltd.</rights><rights>This article is protected by copyright. All rights reserved.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4480-7287d3fbd2502d7b2556db077faa194308b0cdc5b2c38dea11f4c81010e941e93</citedby><cites>FETCH-LOGICAL-c4480-7287d3fbd2502d7b2556db077faa194308b0cdc5b2c38dea11f4c81010e941e93</cites><orcidid>0000-0001-9946-4005</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijcp.14250$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijcp.14250$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33884719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miñana, Bernardino</creatorcontrib><creatorcontrib>Molero, José María</creatorcontrib><creatorcontrib>Agra Rolán, Alfonso</creatorcontrib><creatorcontrib>Martínez‐Fornes, Miguel Téllez</creatorcontrib><creatorcontrib>Cuervo Pinto, Rafael</creatorcontrib><creatorcontrib>Lorite Mingot, David</creatorcontrib><creatorcontrib>Carreño, Ágata</creatorcontrib><creatorcontrib>Palacios‐Moreno, Juan Manuel</creatorcontrib><title>Real‐world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain</title><title>International journal of clinical practice (Esher)</title><addtitle>Int J Clin Pract</addtitle><description>Objectives
This study aimed to describe the real‐world therapeutic management of patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) (LUTS/BPH) attending primary care and urology clinics in Spain.
Methods
This observational, retrospective, multicentre study included men ≥50 years of age diagnosed with LUTS/BPH (≤8 years prior to study visit) (N = 670). Therapeutic management according to healthcare service (primary care vs. urology clinics) or progression criteria, proportion of patients with treatment change, patient profile according to therapy and evolution of LUTS severity were assessed.
Results
Overall differences were noticed in the management of patients between healthcare service (P < .001) and with or without progression criteria (P < .05). Most patients received pharmacological treatment at diagnosis (70.7%; 474/670), which increased at study visit (81.6%; 547/670) with overall similar profiles between primary care and urology clinics for each therapy. α1‐Blockers were the most used pharmacological treatment across healthcare settings at diagnosis (61.8%; 293/474) and study visit (51%; 279/547). Only 27.1% (57/210) of patients with progression criteria at diagnosis and 35.6% (99/278) at study visit received 5α‐reductase inhibitor (5ARI) alone or in combination with a α1‐blocker. Overall, most patients did not change treatment (60%; 402/670) with a trend of more patients worsening in symptoms when not receiving α1‐blocker plus 5ARI combination therapy.
Conclusion
Most patients with LUTS/BPH received pharmacological treatment; however, most men with progression criteria did not receive a 5ARI alone or in combination. These results support the need to reinforce both primary care and urologists existing clinical guideline recommendations for the appropriate medical management of patients with LUTS/BPH.</description><subject>Diagnosis</subject><subject>Disease management</subject><subject>Drug therapy</subject><subject>Genital diseases</subject><subject>Hyperplasia</subject><subject>Original Paper</subject><subject>Original Papers</subject><subject>Patients</subject><subject>Primary care</subject><subject>Urinary tract</subject><subject>Urology</subject><issn>1368-5031</issn><issn>1742-1241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp9kc1u1DAUhS1ERduBDQ-ALLFBlVLs2EmcDVI1otCqEoifteU4NzMeOXawk45m1wUPwDPyJDidoQIWeGPL5_PRPT4IPafknKb12mz0cE55XpBH6IRWPM9ozunjdGalyArC6DE6jXFDSF4UgjxBx4wJwStan6Dvn0DZn3c_tj7YFo9rCGqAaTQa98qpFfTgRqxci-HW23TvHfYdHtRokhDx1oxr3IAzK4eH4OOo5qfr3QBhsCoahc0smF6FHdYqwL3XFLz1q92sfR6UcU_RUadshGeHfYG-Xr79snyf3Xx4d7W8uMk054JkVS6qlnVNm5LmbdWkNGXbkKrqlKI1Z0Q0RLe6aHLNRAuK0o5rQQklUHMKNVugN3vfYWp6aHWKEJSVh_mkV0b-rTizlit_KwUri5KLZPDqYBD8twniKHsTNVirHPgpyrygpWD1PMwCvfwH3fgpuBQvUQXjvEieiTrbUzp9XgzQPQxDiZzLlXO58r7cBL_4c_wH9HebCaB7YGss7P5jJa-ulx_3pr8A3Oezfw</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Miñana, Bernardino</creator><creator>Molero, José María</creator><creator>Agra Rolán, Alfonso</creator><creator>Martínez‐Fornes, Miguel Téllez</creator><creator>Cuervo Pinto, Rafael</creator><creator>Lorite Mingot, David</creator><creator>Carreño, Ágata</creator><creator>Palacios‐Moreno, Juan Manuel</creator><general>Hindawi Limited</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9946-4005</orcidid></search><sort><creationdate>202108</creationdate><title>Real‐world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain</title><author>Miñana, Bernardino ; Molero, José María ; Agra Rolán, Alfonso ; Martínez‐Fornes, Miguel Téllez ; Cuervo Pinto, Rafael ; Lorite Mingot, David ; Carreño, Ágata ; Palacios‐Moreno, Juan Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4480-7287d3fbd2502d7b2556db077faa194308b0cdc5b2c38dea11f4c81010e941e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Diagnosis</topic><topic>Disease management</topic><topic>Drug therapy</topic><topic>Genital diseases</topic><topic>Hyperplasia</topic><topic>Original Paper</topic><topic>Original Papers</topic><topic>Patients</topic><topic>Primary care</topic><topic>Urinary tract</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miñana, Bernardino</creatorcontrib><creatorcontrib>Molero, José María</creatorcontrib><creatorcontrib>Agra Rolán, Alfonso</creatorcontrib><creatorcontrib>Martínez‐Fornes, Miguel Téllez</creatorcontrib><creatorcontrib>Cuervo Pinto, Rafael</creatorcontrib><creatorcontrib>Lorite Mingot, David</creatorcontrib><creatorcontrib>Carreño, Ágata</creatorcontrib><creatorcontrib>Palacios‐Moreno, Juan Manuel</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical practice (Esher)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miñana, Bernardino</au><au>Molero, José María</au><au>Agra Rolán, Alfonso</au><au>Martínez‐Fornes, Miguel Téllez</au><au>Cuervo Pinto, Rafael</au><au>Lorite Mingot, David</au><au>Carreño, Ágata</au><au>Palacios‐Moreno, Juan Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain</atitle><jtitle>International journal of clinical practice (Esher)</jtitle><addtitle>Int J Clin Pract</addtitle><date>2021-08</date><risdate>2021</risdate><volume>75</volume><issue>8</issue><spage>e14250</spage><epage>n/a</epage><pages>e14250-n/a</pages><issn>1368-5031</issn><eissn>1742-1241</eissn><abstract>Objectives
This study aimed to describe the real‐world therapeutic management of patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) (LUTS/BPH) attending primary care and urology clinics in Spain.
Methods
This observational, retrospective, multicentre study included men ≥50 years of age diagnosed with LUTS/BPH (≤8 years prior to study visit) (N = 670). Therapeutic management according to healthcare service (primary care vs. urology clinics) or progression criteria, proportion of patients with treatment change, patient profile according to therapy and evolution of LUTS severity were assessed.
Results
Overall differences were noticed in the management of patients between healthcare service (P < .001) and with or without progression criteria (P < .05). Most patients received pharmacological treatment at diagnosis (70.7%; 474/670), which increased at study visit (81.6%; 547/670) with overall similar profiles between primary care and urology clinics for each therapy. α1‐Blockers were the most used pharmacological treatment across healthcare settings at diagnosis (61.8%; 293/474) and study visit (51%; 279/547). Only 27.1% (57/210) of patients with progression criteria at diagnosis and 35.6% (99/278) at study visit received 5α‐reductase inhibitor (5ARI) alone or in combination with a α1‐blocker. Overall, most patients did not change treatment (60%; 402/670) with a trend of more patients worsening in symptoms when not receiving α1‐blocker plus 5ARI combination therapy.
Conclusion
Most patients with LUTS/BPH received pharmacological treatment; however, most men with progression criteria did not receive a 5ARI alone or in combination. These results support the need to reinforce both primary care and urologists existing clinical guideline recommendations for the appropriate medical management of patients with LUTS/BPH.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>33884719</pmid><doi>10.1111/ijcp.14250</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-9946-4005</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-5031 |
| ispartof | International journal of clinical practice (Esher), 2021-08, Vol.75 (8), p.e14250-n/a |
| issn | 1368-5031 1742-1241 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8365648 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Diagnosis Disease management Drug therapy Genital diseases Hyperplasia Original Paper Original Papers Patients Primary care Urinary tract Urology |
| title | Real‐world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T12%3A07%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90world%20therapeutic%20management%20and%20evolution%20of%20patients%20with%20benign%20prostatic%20hyperplasia%20in%20primary%20care%20and%20urology%20in%20Spain&rft.jtitle=International%20journal%20of%20clinical%20practice%20(Esher)&rft.au=Mi%C3%B1ana,%20Bernardino&rft.date=2021-08&rft.volume=75&rft.issue=8&rft.spage=e14250&rft.epage=n/a&rft.pages=e14250-n/a&rft.issn=1368-5031&rft.eissn=1742-1241&rft_id=info:doi/10.1111/ijcp.14250&rft_dat=%3Cproquest_pubme%3E2553445365%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2553445365&rft_id=info:pmid/33884719&rfr_iscdi=true |